Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia

被引：8

作者：

Owen, C. ^{[1
]}

Gerrie, A. S. ^{[2
,3
]}

Banerji, V ^{[4
]}

Assouline, S. ^{[5
,6
]}

Chen, C. ^{[7
,8
]}

Robinson, K. S. ^{[9
,10
]}

Lye, E. ^{[11
]}

Fraser, G. ^{[12
,13
]}

机构：

[1] Foothills Med Ctr, Div Hematol & Hematol Malignancies, Calgary, AB, Canada

[2] Univ British Columbia, Div Med Oncol, Vancouver, BC, Canada

[3] BC Canc, Vancouver, BC, Canada

[4] Canc Care Manitoba, Dept Hematol & Med Oncol, Winnipeg, MB, Canada

[5] McGill Univ, Dept Med Oncol, Montreal, PQ, Canada

[6] Jewish Gen Hosp, Montreal, PQ, Canada

[7] Univ Toronto, Dept Med Oncol, Toronto, ON, Canada

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Dalhousie Univ, Div Hematol, Halifax, NS, Canada

[10] QEII Hlth Sci Ctr, Halifax, NS, Canada

[11] Lymphoma Canada, Mississauga, ON, Canada

[12] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

[13] Juravinski Canc Ctr, Hamilton, ON, Canada

来源：

CURRENT ONCOLOGY | 2018年 / 25卷 / 05期

关键词：

Chronic lymphocytic leukemia; CLL; treatment; prognosis; fitness; PREVIOUSLY UNTREATED PATIENTS; PROGRESSION-FREE SURVIVAL; PHASE-II TRIAL; OPEN-LABEL; INITIAL THERAPY; PROGNOSTIC INDEX; CLL-IPI; MAINTENANCE RITUXIMAB; OLDER PATIENTS; FLUDARABINE;

D O I：

10.3747/co.25.4092

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in North America. In Canada, no unified national guideline exists for the front-line treatment of CLL; provincial guidelines vary and are largely based on funding. A group of clinical experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of CLL. Consensus recommendations based on available evidence are presented for the first-line treatment of CLL.

引用

页码：E461 / E474

页数：14

共 86 条

[1] Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia [J].

Abrisqueta, Pau ;

Villamor, Neus ;

Jose Terol, Maria ;

Gonzalez-Barca, Eva ;

Gonzalez, Marcos ;

Ferra, Christelle ;

Abella, Eugenia ;

Delgado, Julio ;

Garcia-Marco, Jose A. ;

Gonzalez, Yolanda ;

Carbonell, Felix ;

Ferrer, Secundino ;

Monzo, Encarna ;

Jarque, Isidro ;

Muntanola, Ana ;

Constants, Mireia ;

Escoda, Lourdes ;

Calvo, Xavier ;

Bobillo, Sabela ;

Bruno Montoro, Jose ;

Montserrat, Emili ;

Bosch, Francesc .

BLOOD, 2013, 122 (24) :3951-3959

[2]

[Anonymous], EUPDATE CHRON LYMPH

[3]

[Anonymous], NUMB RAT NEW CAS PRI

[4]

[Anonymous], J CLIN ONCOL

[5]

[Anonymous], HLTH PROF INF CANC M

[6]

[Anonymous], 2015, LEUKEMIA, DOI DOI 10.1038/leu.2014.196

[7]

[Anonymous], CHRON LYMPH LEUK

[8]

[Anonymous], PRACT GUID DIS MAN C

[9]

[Anonymous], CANC STAT FACTS LEUK

[10]

[Anonymous], CHRONISCHE LYMPHATIS

← 1 2 3 4 5 6 7 8 9 →